NOMADS UAB, Lithuania Published Milestone Research Paper Describing its Novel Klebicin Product Candidates for Control of Pathogenic Klebsiella
NOMADS UAB, Lithuania, NOMAD Bioscience’s wholly owned subsidiary, announces the publication in the Scientific Reports journal (Denkovskienė E, Paškevičius Š, Misiūnas A, Stočkūnaitė B, Starkevič U, Vitkauskienė A, Hahn-L bmann S, Schulz S, Giritch A, Gleba Y, Ražanskienė A. Broad and efficient control of Klebsiella pathogens by peptidoglycan-degrading and pore-forming bacteriocins Klebicins. Scientific Reports (2019) 9: 15422; https://www.nature.com/articles/s41598-019-51969-1) a research paper describing novel antibacterial proteins Klebicins that provide broad and efficient control of major pathogenic strains of Klebsiella.
Gram-negative bacteria belonging to the genus Klebsiella are important nosocomial pathogens, readily acquiring resistance to all known antibiotics. Bacteriocins, non-antibiotic antibacterial proteins, have been earlier proposed as potential therapeutic agents for control of other Gram-negative species such as Escherichia, Pseudomonas and Salmonella.
NOMADS scientists discovered, cloned, expressed in plants and characterized nine pore-forming and peptidoglycan-degrading bacteriocins from different Klebsiella species which they termed Klebicins. The results published in Nature Scientific Reports journal demonstrate that Klebicins are expressed at very high yields in green plants and exhibit high genus-specific antimicrobial activity on both planktonic and biofilm-embedded cells. The panel of six highly efficient plant-expressed Klebicins control 94% of over 100 clinical isolates evaluated. Most importantly, Klebicins are active against most of the tested multidrug-resistant (MDR) bacterial pathovars including those insensitive to the last generation antibiotics carbapenems and cephalosporins. Klebicins are thus promising non-antibiotic antibacterial agents and could be the basis of novel therapies for control of MDR Klebsiella.
About NOMADS UAB.
Nomads UAB is a biotechnology company developing new non-antibiotic antibacterials, including bacteriocins and endolysins, to be used as pharmaceuticals, food additives and medical devices.
About NOMAD Bioscience GmbH.
Nomad Bioscience GmbH, parent company of NOMADS, is a plant biotechnology company developing a broad range of biotechnology products manufactured in plants. Corporate offices are headquartered in Munich, Germany and the Company’s Research Division is located in Halle, Germany.
